Myriad Genetics, Inc. (MYGN)
4.29
+0.20
(+4.89%)
USD |
NASDAQ |
May 08, 16:00
4.285
0.00 (0.00%)
After-Hours: 20:00
Myriad Genetics Shareholders Equity (Quarterly) : 337.40M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Celldex Therapeutics, Inc. | 456.23M |
| Plus Therapeutics, Inc. | 3.996M |
| Perspective Therapeutics, Inc. | 207.03M |
| Atossa Therapeutics, Inc. | 30.49M |
| AVITA Medical, Inc. | -16.65M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 673.70M |
| Total Liabilities (Quarterly) | 336.30M |
| Debt to Equity Ratio | 0.6269 |
| Current Ratio | 2.402 |
| Net Debt Paydown Yield | -3.35% |